Mano Michael 4
4 · Karyopharm Therapeutics Inc. · Filed Feb 3, 2026
Research Summary
AI-generated summary of this filing
Karyopharm (KPTI) EVP Mano Michael Receives 32,415 RSU Award
What Happened
Mano Michael, EVP, Chief Legal Officer & Secretary of Karyopharm Therapeutics Inc. (KPTI), was granted 32,415 restricted stock units (RSUs) on January 31, 2026. The award is recorded on the Form 4 as an acquisition at $0.00 per share (total reported cash paid = $0). This is an equity award (grant) rather than a purchase or sale.
Key Details
- Transaction date: 2026-01-31; Form 4 filed 2026-02-03 (no late filing indicated in the filing).
- Transaction type/code: A = Award/Grant (RSUs). Reported acquisition price: $0.00.
- Shares granted: 32,415 RSUs (convert one-for-one to common stock upon vesting).
- Shares owned after transaction: Not disclosed in this filing.
- Footnote: RSUs vest 50% on January 31, 2027 and the remaining 50% on January 31, 2028 (per the company’s 2022 Equity Incentive Plan, as amended).
Context
RSU grants are compensation and do not require an upfront cash outlay by the insider; they only convert to actual shares when they vest. The reported $0 acquisition price on Form 4 is standard for RSU awards and does not reflect future market value, which depends on KPTI’s stock price at vesting.
Insider Transaction Report
- Award
Common Stock
[F1]2026-01-31+32,415→ 97,490 total
Footnotes (1)
- [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028.